Press releases

Share this press release :  facebook  twitter  linkedin  google+
Quantum Genomics extends its collaboration agreement with its partner in animal health   (28/06/2016 18:00)

Companies to continue joint development of therapies to treat heart failure in dogs
 

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has extended its collaboration agreement with its partner, a world leader in animal health.

Under this agreement, the two companies will continue working together to initiate additional clinical trials of the drug candidate developed by Quantum Genomics for the treatment of heart failure in dogs. The specific financial terms of the contact remain undisclosed.

Lionel Segard, Quantum Genomics' President and Chief Executive Officer, commented:

“The goal of this partnership is to overcome heart failure challenges in dogs. We are pleased to extend our collaboration with a major player in the industry and continue the evaluation of veterinary applications for our unique therapeutic candidates. We believe such collaborative veterinary clinical development efforts will further strengthen our position in the field of heart failure, at a time when we are launching our Phase IIa trial in humans.”
 

CONTACTS
Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
 
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
 
ACTUS finance et communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr
 
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592

 

ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
 


Powered by Actusnews Wire (press release services) ©